NovaBay Pharmaceuticals, Inc. Annual Report - How They Did This Year

Hey there!

You want to understand NovaBay Pharmaceuticals, Inc. and its investment potential. That's a smart move! I'll be your friendly guide. I'll help you cut through financial jargon and get to what matters.

We'll build this report together, piece by piece. We'll use information from NovaBay's filings. I'll explain everything simply, like talking to a friend over coffee.

We just got our first look at NovaBay's annual report for Fiscal Year 2025. This year ended on December 31st, 2025. Wow, some interesting things are happening! NovaBay is undergoing a big transformation.

Here's what we're learning so far:

• What does this company do and how did they perform this year?

  • Here's the biggest news! NovaBay is making a major strategic shift. NovaBay used to be a biopharmaceutical company. It developed and sold products for eye and skin care. Its main product, Avenova, was an antimicrobial spray for eye conditions. Now, they are selling off their traditional pharmaceutical businesses. For example, they sold their Dermadoctor assets in March 2024. These included dermatologist-developed skincare products. Next, they sold their WoundCare business in January 2025. They also sold their main Avenova assets in January 2025. These sales mean they completely left their established pharma and consumer health products.
  • Instead, they are moving into "blockchain networks and digital assets." This means they are getting into things like SKYTokens. These could be utility or governance tokens for a special blockchain network. They are also working with USDSTokens and USDTTokens. These are likely stablecoins, meant to keep a steady value against the U.S. dollar. This is a huge change from being a pharma company! They are moving from regulated healthcare products to the speculative and volatile digital asset world.
  • This "business realignment" is a big gamble. It means their traditional pharma performance is likely ending as they change direction. Selling their main income-producing assets means a big drop, or even an end, to traditional pharmaceutical sales for 2025 and beyond. We don't have performance numbers for the new digital asset business yet. It's still very new. But they are clearly leaving their old identity and its income sources behind.

• Financial performance - revenue, profit, growth metrics

  • Selling major parts of their business suggests a big financial change. They sold their Dermadoctor, WoundCare, and Avenova assets. This means the company lost its main sources of product income. This points to a big drop in traditional revenue for Fiscal Year 2025. These assets were their core business. The company is essentially starting fresh to make money from its new digital asset focus.
  • They have actively raised money in many ways. Companies often do this during big shifts or when they need cash. This includes issuing different types of preferred stock. These are special shares, like Series F, E, D, and B. They usually come with specific rights, dividends, and can often turn into regular shares. They also issued many warrants. Warrants are like options. They let investors buy company shares at a set price later. This brings in future cash if used, but it can also mean more shares issued, reducing your ownership percentage.
  • They also took out bridge loans in late 2024 and early 2025. These are short-term loans. Companies use them for immediate cash needs while arranging longer-term funding. These loans usually have higher interest rates. They can show urgent cash needs. This might mean cash flow was tight during this change. It forced them to get quick capital.
  • They also did "warrant reprice transactions." This usually means lowering the price to buy shares later. This encourages investors to use their warrants and brings in cash. It often signals that the stock price has fallen below the original purchase price. Also, a "2024 Public Offering" means they sold new shares to the public to raise money. This is a common way to get funds, but it means more shares issued, reducing your ownership percentage.

• Major wins and challenges this year

  • Major Win (Potential): The bold move into digital assets could be a big success if it works out. This change completely reinvents the company. It aims for markets with potentially higher growth than traditional pharmaceuticals. They even created a Digital Asset Strategy Advisory Committee. This committee will oversee the new direction. This shows a formal commitment and strategic focus on this new venture.
  • Major Challenges: Selling core assets means leaving behind established income sources. These sources might have been underperforming. This creates a big income gap and removes predictable money. The need for so much complex funding suggests they are working hard to fund this change. They need to keep the company going. This points to significant financial strain. It also shows a reliance on outside money to keep operations running during this transformation.

• Financial health - cash, debt, liquidity

  • The bridge loans and constant issuing of different stocks and warrants show the company is actively seeking money. This isn't always bad for a growth company. But here, it suggests they need cash to support operations and their new plan. This is likely due to negative cash flow and transformation costs. This reliance on outside funding points to potential cash problems. This could lead to auditors questioning if the company can continue operating.
  • A big piece of news for early 2026 (after the fiscal year ended) is a reverse stock split. This happened on February 20, 2026. A reverse stock split reduces the total number of shares available. This usually increases the price per share proportionally. Companies often do this to meet stock exchange rules. For example, they might need to keep a minimum share price, like $1.00 for Nasdaq. While it raises the share price, it doesn't change the company's total market value. It can sometimes signal financial struggles or a stock that has performed poorly.

• Key risks that could hurt the stock price

  • Strategic Pivot Risk: Moving from pharma to blockchain is a huge change. It needs new expertise, systems, and market knowledge. The digital asset world is very new, volatile, and has unclear, fast-changing rules. This is a high-risk, high-reward move. There's no guarantee of success or market acceptance for their new digital products. The company has no proven history in this area. It faces strong competition from existing crypto players.
  • Dilution Risk: They are issuing preferred stock, warrants, and convertible notes. These can turn into regular shares. This means the number of shares available could increase a lot. Your ownership percentage in the company could get smaller. This can happen even if the company's value stays the same or grows. It would reduce earnings per share and voting power for current shareholders. The At-The-Market Offering Agreement lets the company sell shares directly into the market over time. This creates ongoing selling pressure. The January 2026 Private Placement involves selling shares to a select group of investors. This is often at a discount. Both add to the potential for more shares issued, reducing your ownership percentage.
  • Financial Strain: The constant need for bridge loans and complex funding shows ongoing cash needs. It also points to potential negative cash flow. This raises worries about the company's long-term ability to survive. It questions their ability to fund the new strategy without continuous, potentially dilutive, capital raises. This could lead to auditors questioning if the company can continue operating.
  • Cybersecurity Risk: Their new focus on digital assets and blockchain makes cybersecurity even more critical. The company knows this. Management and the Board oversee these risks. But hacks, theft of digital assets, or service disruptions from cyberattacks could happen. These could cause big financial losses, harm their reputation, and make investors lose trust.

• Leadership or strategy changes

  • The "business realignment" and the new "Digital Asset Strategy Advisory Committee" clearly signal a major strategic shift. This means a complete overhaul of the company's business model and main operations. It's not just a product change. It's a fundamental transformation. Management, including the CEO and CFO, directly oversee the risks of this new path. This highlights their strong commitment to this new, unproven strategy.

• Future outlook

  • NovaBay's future clearly depends on its move into blockchain and digital assets. They sold their traditional pharmaceutical assets. Now, the company's survival and growth rely entirely on market acceptance. They also need successful execution of their digital asset strategy. They are actively raising money and changing their business to support this new venture. The success of SKYTokens, USDSTokens, and USDTTokens will be key. They need strong market adoption and clear regulations to make real money and become profitable. The outlook is very speculative. It's either a big success or a big failure. There's potential for significant gains if the change works. But there's also a big risk of failure, given the competitive and volatile digital asset market.

• Market trends or regulatory changes affecting them

  • The digital asset and blockchain market is still changing fast. New technologies and rules constantly appear. This means NovaBay will operate in a very dynamic and possibly unpredictable environment. Key trends include more big institutions using digital assets. But there's also increased scrutiny from regulators like the SEC. They are looking closely at how tokens are classified and how stablecoins are overseen. International rules also matter a lot. The natural volatility of cryptocurrency markets will directly affect how NovaBay's new digital assets are valued and how stable they seem.

This first bit of information tells us NovaBay is no longer the pharma company it once was. It's transforming into something new. This comes with all the risks and potential rewards of such a big change. Remember, a reverse stock split and heavy reliance on complex funding can be red flags. But the digital asset pivot could also be a bold, high-risk, high-reward move for future growth. The company has essentially bet its entire future on this new, unproven venture. It has shed its traditional income sources.